Russian scientists developing innovative hepatitis B drug

30 July 2018

Russian scientists are working on the development of an innovative drug against hepatitis B that can be considered as a breakthrough in the global market for such drugs, according to scientists and experts of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.

It is reported the new drug should be officially launched in the market during the next two to three years. It will have anthebility to destroy the virus inside the liver cells and to treat even chronic forms of the disease. Pre-clinical trials of the drug will begin in 2019.

According to the Russian Ministry of Health, currently there are no such drugs in the world, while the existing range of global drugmakers specializing on the production of such drugs, is limited by only medicines that suppress the virus, not completely removing it from patient’s body. According to state data, currently more than 250 million people worldwide suffer from chronic hepatitis B. Of these, 3 million live in Russia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK